aTyr Pharma's Total Assets for the quarter that ended in Dec. 2023 was $120.65 Mil.
During the past 12 months, aTyr Pharma's average Total Assets Growth Rate was -24.10% per year.
During the past 3 years, the average Total Assets Growth Rate was 47.30% per year.
During the past 5 years, the average Total Assets Growth Rate was 54.10% per year.
During the past 10 years, the average Total Assets Growth Rate was 11.70% per year.
During the past 11 years, aTyr Pharma's highest 3-Year average Total Assets Growth Rate was 80.50%. The lowest was -54.60%. And the median was 26.00%.
Total Assets is connected with ROA %. aTyr Pharma's annualizedROA % for the quarter that ended in Dec. 2023 was -48.05%. Total Assets is also linked to Revenue through Asset Turnover. aTyr Pharma's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.
aTyr Pharma Total Assets Historical Data
The historical data trend for aTyr Pharma's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
aTyr Pharma Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Total Assets
36.19
38.73
115.54
95.79
120.65
aTyr Pharma Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Total Assets
95.79
136.84
132.75
125.07
120.65
aTyr Pharma Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
aTyr Pharma's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
aTyr Pharma's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
aTyr Pharma Total Assets Related Terms
Thank you for viewing the detailed overview of aTyr Pharma's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LIFE has been successfully added to your 